Key Points
- To determine whether thromboxane A2 feedback amplification is required to trigger secondary aggregation and granule release when platelets make close contact in a low-calcium environment.
- Washed human platelets and resuspended them in a modified Tyrode solution containing low ionized calcium (20 µmol/L) and 1 mmol/L magnesium.
- Induced platelet-to-platelet contact using adenosine diphosphate with fibrinogen, polylysine agglutination, or chymotrypsin pretreatment with fibrinogen.
- Tested secondary aggregation and granule release after introducing physiological calcium (1 to 2 mmol/L), aspirin, the receptor antagonist BM 13.177, or the thromboxane synthesis inhibitor dazoxiben.
- In low-calcium media, close contact induced by weak agonists provoked secondary aggregation, granule content release, and robust thromboxane A2 formation.
- Restoring calcium to physiological levels (1 to 2 mmol/L), adding aspirin, or blocking thromboxane receptors with BM 13.177 completely prevented secondary aggregation and secretion.
- Dazoxiben reduced thromboxane A2 formation without preventing secondary aggregation, while aspirin-treated platelets maintained baseline responsiveness, confirming dependence on prostaglandin endoperoxides or thromboxane A2 amplification.
Structured PICO
PPopulationHuman platelets washed and resuspended in modified Tyrode solution
IInterventionWeak agonists (ADP, polylysine, chymotrypsin) in low-calcium medium (20 mumol/L Ca2+)
CComparatorPhysiological calcium medium (1-2 mmol/L Ca2+) or addition of aspirin, BM 13.177, or dazoxiben
OOutcomeSecondary aggregation, TXA2 formation, and release of granule contentssurrogate
Secondary platelet aggregation responses to weak agonists observed in citrated plasma (low calcium) do not occur at physiological calcium concentrations, suggesting they may have little biological relevance in circulating blood.